Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Real-time Estimate Cboe BZX Other stock markets 11:44:24 2024-04-30 am EDT			5-day change	1st Jan Change
4.175 ^USD	-2.00%		+0.60%	+14.97%

12:05pm	MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	CI
Apr. 29	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	06:05am	AQ
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease	Apr. 29	AQ
MannKind Repays Certain Debt Obligations	Apr. 03	AQ
MannKind Announces CFO Transition	Mar. 26	AQ
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	Mar. 11	AQ
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	Mar. 05	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	Mar. 04	AQ
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	Feb. 27	AQ
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	Feb. 20	AQ
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	AQ
MannKind Announces Up To $200 Million Royalty Purchase Agreement With Sagard Healthcare	Jan. 09	AQ
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million	Jan. 02	AQ
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference	Dec. 28	AQ
MannKind : HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT - Form 8-K	Dec. 27	PU
MannKind: Q3 Earnings Snapshot	Nov. 07	AQ
MannKind Corporation Reports 2023 Third Quarter Financial Results	Nov. 07	AQ
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes	Nov. 06	AQ
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023	23-10-31	AQ
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent	23-10-30	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	23-09-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Press Releases

Filters